JP2007526291A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007526291A5 JP2007526291A5 JP2007501345A JP2007501345A JP2007526291A5 JP 2007526291 A5 JP2007526291 A5 JP 2007526291A5 JP 2007501345 A JP2007501345 A JP 2007501345A JP 2007501345 A JP2007501345 A JP 2007501345A JP 2007526291 A5 JP2007526291 A5 JP 2007526291A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pain
- dose
- formula
- adenosine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 189
- 238000004519 manufacturing process Methods 0.000 claims 27
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 208000002193 Pain Diseases 0.000 claims 24
- -1 2,2,3,3-tetrafluoro-cyclobutyl Chemical group 0.000 claims 20
- 206010061218 Inflammation Diseases 0.000 claims 20
- 230000000694 effects Effects 0.000 claims 20
- 230000004054 inflammatory process Effects 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 19
- 239000007795 chemical reaction product Substances 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 12
- 230000002265 prevention Effects 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 11
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 230000036470 plasma concentration Effects 0.000 claims 10
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 10
- 201000001320 Atherosclerosis Diseases 0.000 claims 8
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 8
- 206010040070 Septic Shock Diseases 0.000 claims 8
- 206010012601 diabetes mellitus Diseases 0.000 claims 8
- 206010063837 Reperfusion injury Diseases 0.000 claims 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 7
- 230000006378 damage Effects 0.000 claims 7
- 208000030507 AIDS Diseases 0.000 claims 6
- 108050000203 Adenosine receptors Proteins 0.000 claims 6
- 102000009346 Adenosine receptors Human genes 0.000 claims 6
- 206010002383 Angina Pectoris Diseases 0.000 claims 6
- 206010006895 Cachexia Diseases 0.000 claims 6
- 208000001953 Hypotension Diseases 0.000 claims 6
- 208000007101 Muscle Cramp Diseases 0.000 claims 6
- 208000001871 Tachycardia Diseases 0.000 claims 6
- 230000036471 bradycardia Effects 0.000 claims 6
- 208000006218 bradycardia Diseases 0.000 claims 6
- 230000036543 hypotension Effects 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 6
- 208000028867 ischemia Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 6
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 6
- 201000008482 osteoarthritis Diseases 0.000 claims 6
- 230000006794 tachycardia Effects 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 5
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 claims 5
- 201000005569 Gout Diseases 0.000 claims 5
- 241001465754 Metazoa Species 0.000 claims 5
- 125000001246 bromo group Chemical group Br* 0.000 claims 5
- 239000002988 disease modifying antirheumatic drug Substances 0.000 claims 5
- 210000004072 lung Anatomy 0.000 claims 5
- 102000007471 Adenosine A2A receptor Human genes 0.000 claims 4
- 108010085277 Adenosine A2A receptor Proteins 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical group CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 claims 4
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 4
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 4
- 206010049565 Muscle fatigue Diseases 0.000 claims 4
- 206010040047 Sepsis Diseases 0.000 claims 4
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 4
- 208000005392 Spasm Diseases 0.000 claims 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 4
- 208000027418 Wounds and injury Diseases 0.000 claims 4
- 230000008484 agonism Effects 0.000 claims 4
- 206010003119 arrhythmia Diseases 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims 4
- 206010015037 epilepsy Diseases 0.000 claims 4
- 208000014674 injury Diseases 0.000 claims 4
- 210000004185 liver Anatomy 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 230000004770 neurodegeneration Effects 0.000 claims 4
- 208000021722 neuropathic pain Diseases 0.000 claims 4
- 230000001575 pathological effect Effects 0.000 claims 4
- 230000008695 pulmonary vasoconstriction Effects 0.000 claims 4
- 230000036303 septic shock Effects 0.000 claims 4
- 241000894007 species Species 0.000 claims 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 3
- 208000008035 Back Pain Diseases 0.000 claims 3
- 206010063094 Cerebral malaria Diseases 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 201000004624 Dermatitis Diseases 0.000 claims 3
- 206010018634 Gouty Arthritis Diseases 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 3
- 208000037357 HIV infectious disease Diseases 0.000 claims 3
- 208000007514 Herpes zoster Diseases 0.000 claims 3
- 208000004454 Hyperalgesia Diseases 0.000 claims 3
- 208000035154 Hyperesthesia Diseases 0.000 claims 3
- 206010065390 Inflammatory pain Diseases 0.000 claims 3
- 206010027202 Meningitis bacterial Diseases 0.000 claims 3
- 208000000112 Myalgia Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 206010033799 Paralysis Diseases 0.000 claims 3
- 206010037660 Pyrexia Diseases 0.000 claims 3
- 201000010001 Silicosis Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 230000001668 ameliorated effect Effects 0.000 claims 3
- 201000009904 bacterial meningitis Diseases 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 208000019664 bone resorption disease Diseases 0.000 claims 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 3
- 230000000968 intestinal effect Effects 0.000 claims 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 3
- 230000000302 ischemic effect Effects 0.000 claims 3
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 3
- 208000011379 keloid formation Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 230000010412 perfusion Effects 0.000 claims 3
- 231100000241 scar Toxicity 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 230000000451 tissue damage Effects 0.000 claims 3
- 231100000827 tissue damage Toxicity 0.000 claims 3
- 230000009772 tissue formation Effects 0.000 claims 3
- BIXYYZIIJIXVFW-UUOKFMHZSA-N (2R,3R,4S,5R)-2-(6-amino-2-chloro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O BIXYYZIIJIXVFW-UUOKFMHZSA-N 0.000 claims 2
- JANKFBXROBYGIA-JJNLEZRASA-N (2r,3r,4r,5r)-5-(6-amino-2-ethylpurin-9-yl)-2-(hydroxymethyl)-4-sulfanyloxolan-3-ol Chemical compound C12=NC(CC)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1S JANKFBXROBYGIA-JJNLEZRASA-N 0.000 claims 2
- XLFPEGIAPOEGML-PRDAMCLASA-N 2-[(2r,3s,4r,5s)-5-(6-amino-2-nitropurin-9-yl)-2,3,4,5-tetrabenzoyl-3,4-dihydroxyoxolan-2-yl]-2-hydroxy-1-phenylethanone Chemical compound OC([C@@]1(C(=O)C=2C=CC=CC=2)O[C@]([C@@]([C@]1(C(=O)C=1C=CC=CC=1)O)(O)C(=O)C=1C=CC=CC=1)(N1C=2N=C(N=C(C=2N=C1)N)[N+]([O-])=O)C(=O)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 XLFPEGIAPOEGML-PRDAMCLASA-N 0.000 claims 2
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000000884 Airway Obstruction Diseases 0.000 claims 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims 2
- 206010002329 Aneurysm Diseases 0.000 claims 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 208000036487 Arthropathies Diseases 0.000 claims 2
- 206010061666 Autonomic neuropathy Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010006482 Bronchospasm Diseases 0.000 claims 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 206010059109 Cerebral vasoconstriction Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 2
- 208000000059 Dyspnea Diseases 0.000 claims 2
- 206010013975 Dyspnoeas Diseases 0.000 claims 2
- 208000005189 Embolism Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 206010014824 Endotoxic shock Diseases 0.000 claims 2
- 208000007530 Essential hypertension Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010058179 Hypertensive emergency Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 208000004575 Infectious Arthritis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 102100020873 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 206010022562 Intermittent claudication Diseases 0.000 claims 2
- 208000012659 Joint disease Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000016604 Lyme disease Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010061876 Obstruction Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000000450 Pelvic Pain Diseases 0.000 claims 2
- 208000004550 Postoperative Pain Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 208000007718 Stable Angina Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010071436 Systolic dysfunction Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 208000001435 Thromboembolism Diseases 0.000 claims 2
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 208000024248 Vascular System injury Diseases 0.000 claims 2
- 208000012339 Vascular injury Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- AWVZGUNRNMIGRW-NQHNHUSUSA-N [(2R,3S,4S,5S)-4,5-diacetyloxy-5-(6-amino-6-chloro-2-nitro-8H-purin-9-yl)-3,4-dihydroxy-2-(hydroxymethyl)oxolan-3-yl] acetate Chemical compound C(C)(=O)O[C@@]1([C@]([C@@](O[C@@H]1CO)(N1CN=C2C(N)(N=C(N=C12)[N+](=O)[O-])Cl)OC(C)=O)(O)OC(C)=O)O AWVZGUNRNMIGRW-NQHNHUSUSA-N 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims 2
- 229960003942 amphotericin b Drugs 0.000 claims 2
- 238000002399 angioplasty Methods 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 230000006793 arrhythmia Effects 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 206010003230 arteritis Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 230000007885 bronchoconstriction Effects 0.000 claims 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 206010014599 encephalitis Diseases 0.000 claims 2
- 210000003979 eosinophil Anatomy 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 230000002008 hemorrhagic effect Effects 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 208000000509 infertility Diseases 0.000 claims 2
- 230000036512 infertility Effects 0.000 claims 2
- 231100000535 infertility Toxicity 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 2
- 208000001286 intracranial vasospasm Diseases 0.000 claims 2
- 208000037906 ischaemic injury Diseases 0.000 claims 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 2
- 210000004153 islets of langerhan Anatomy 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000030175 lameness Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000003866 lung sarcoma Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 201000005857 malignant hypertension Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 208000013465 muscle pain Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 2
- 230000003961 neuronal insult Effects 0.000 claims 2
- 210000000440 neutrophil Anatomy 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000008494 pericarditis Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 208000008423 pleurisy Diseases 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- 201000001223 septic arthritis Diseases 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 206010042772 syncope Diseases 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 231100000397 ulcer Toxicity 0.000 claims 2
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 claims 1
- HAECNPAZKHPFNF-KQYNXXCUSA-N (2r,3r,4s,5r)-2-(6-amino-2-chloro-8-methylpurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound CC1=NC2=C(N)N=C(Cl)N=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HAECNPAZKHPFNF-KQYNXXCUSA-N 0.000 claims 1
- MGEBVSZZNFOIRB-UUOKFMHZSA-N (2r,3r,4s,5r)-2-(6-amino-2-iodopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(I)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O MGEBVSZZNFOIRB-UUOKFMHZSA-N 0.000 claims 1
- AJACDNCVEGIBNA-KQYNXXCUSA-N (2r,3r,4s,5r)-2-(6-amino-2-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C12=NC(OC)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O AJACDNCVEGIBNA-KQYNXXCUSA-N 0.000 claims 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 claims 1
- AKQMZZOTFNLAQJ-UHFFFAOYSA-N 1,1,2,2-tetrafluorocyclobutane Chemical compound FC1(F)CCC1(F)F AKQMZZOTFNLAQJ-UHFFFAOYSA-N 0.000 claims 1
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 claims 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 claims 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 1
- AJACDNCVEGIBNA-UHFFFAOYSA-N 2-Methoxyadenosine Natural products C12=NC(OC)=NC(N)=C2N=CN1C1OC(CO)C(O)C1O AJACDNCVEGIBNA-UHFFFAOYSA-N 0.000 claims 1
- SCNILGOVBBRMBK-SDBHATRESA-N 2-Phenylaminoadenosine Chemical compound N=1C=2N([C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C=NC=2C(N)=NC=1NC1=CC=CC=C1 SCNILGOVBBRMBK-SDBHATRESA-N 0.000 claims 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 claims 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 claims 1
- 208000037859 AIDS-related disorder Diseases 0.000 claims 1
- 206010000087 Abdominal pain upper Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 claims 1
- 206010028836 Neck pain Diseases 0.000 claims 1
- 101100109871 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aro-8 gene Proteins 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033647 Pancreatitis acute Diseases 0.000 claims 1
- 206010061339 Perineal pain Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 206010065016 Post-traumatic pain Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 206010038419 Renal colic Diseases 0.000 claims 1
- 206010038563 Reocclusion Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 208000028911 Temporomandibular Joint disease Diseases 0.000 claims 1
- JDGVNEYLIFLUJP-LSFOPHAVSA-N [(2R,3S,4S,5S)-4,5-diacetyloxy-5-(6-amino-6-chloro-8H-purin-9-yl)-3,4-dihydroxy-2-(hydroxymethyl)oxolan-3-yl] acetate Chemical compound ClC1(C2=NCN([C@]3([C@](O)([C@](O)([C@@H](CO)O3)OC(C)=O)OC(C)=O)OC(C)=O)C2=NC=N1)N JDGVNEYLIFLUJP-LSFOPHAVSA-N 0.000 claims 1
- DTCLZDMQJYIZBY-POXJXICBSA-N [(2S,4R,5S)-5-(6-amino-2-nitropurin-9-yl)-3,4,5-tribenzoyl-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-phenylmethanone Chemical compound C(C1=CC=CC=C1)(=O)C1([C@]([C@@](O[C@@H]1CO)(N1C=NC=2C(N)=NC(=NC1=2)[N+](=O)[O-])C(C1=CC=CC=C1)=O)(O)C(C1=CC=CC=C1)=O)C(C1=CC=CC=C1)=O DTCLZDMQJYIZBY-POXJXICBSA-N 0.000 claims 1
- 201000003229 acute pancreatitis Diseases 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 229940127113 compound 57 Drugs 0.000 claims 1
- 229940125900 compound 59 Drugs 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- ISQVBYGGNVVVHB-UHFFFAOYSA-N cyclopentylmethanol Chemical compound OCC1CCCC1 ISQVBYGGNVVVHB-UHFFFAOYSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 claims 1
- 210000004705 lumbosacral region Anatomy 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 208000030613 peripheral artery disease Diseases 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- QJDUDPQVDAASMV-UHFFFAOYSA-M sodium;ethanethiolate Chemical compound [Na+].CC[S-] QJDUDPQVDAASMV-UHFFFAOYSA-M 0.000 claims 1
- 208000005198 spinal stenosis Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2004/000902 WO2004079329A2 (en) | 2003-03-07 | 2004-03-05 | Identification of therapeutic compounds |
| GB0405012A GB0405012D0 (en) | 2004-03-05 | 2004-03-05 | Therapeutic compounds |
| GBGB0405009.2A GB0405009D0 (en) | 2004-03-05 | 2004-03-05 | Analgesics |
| GB0412262A GB0412262D0 (en) | 2004-06-02 | 2004-06-02 | Use of compounds for the treatment of pain |
| GB0412261A GB0412261D0 (en) | 2004-06-02 | 2004-06-02 | Analgesics |
| GB0413627A GB0413627D0 (en) | 2004-06-18 | 2004-06-18 | Analgesics |
| GB0419718A GB0419718D0 (en) | 2004-09-06 | 2004-09-06 | Therapeutic compounds |
| GB0420063A GB0420063D0 (en) | 2004-09-09 | 2004-09-09 | Therapeutic compounds |
| GB0420615A GB0420615D0 (en) | 2004-09-16 | 2004-09-16 | Therapeutic compounds |
| PCT/GB2005/000800 WO2005084653A2 (en) | 2004-03-05 | 2005-03-04 | Adenosine receptor agonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011280200A Division JP2012102114A (ja) | 2004-03-05 | 2011-12-21 | アデノシン受容体アゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007526291A JP2007526291A (ja) | 2007-09-13 |
| JP2007526291A5 true JP2007526291A5 (enExample) | 2008-04-17 |
Family
ID=34923594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007501345A Pending JP2007526291A (ja) | 2004-03-05 | 2005-03-04 | アデノシン受容体アゴニスト |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080221060A1 (enExample) |
| EP (1) | EP1749016A2 (enExample) |
| JP (1) | JP2007526291A (enExample) |
| KR (1) | KR20070004792A (enExample) |
| AU (1) | AU2005218997B2 (enExample) |
| BR (1) | BRPI0508488A (enExample) |
| CA (1) | CA2557285A1 (enExample) |
| EA (2) | EA014425B1 (enExample) |
| MX (1) | MXPA06010075A (enExample) |
| NO (1) | NO20064365L (enExample) |
| SG (1) | SG144146A1 (enExample) |
| WO (1) | WO2005084653A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1434782A2 (en) | 2001-10-01 | 2004-07-07 | University of Virginia Patent Foundation | 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
| GB0228723D0 (en) | 2002-12-09 | 2003-01-15 | Cambridge Biotechnology Ltd | Treatment of pain |
| EP1746885A4 (en) * | 2004-05-03 | 2010-09-08 | Univ Virginia | AGONISTS OF A2A ADENOSINE RECEPTORS FOR THE TREATMENT OF NEEDLE INJURY IN DIABETES |
| GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| CA2586845A1 (en) * | 2004-11-08 | 2006-05-11 | Can-Fite Biopharma Ltd. | Therapeutic treatment of accelerated bone resorption |
| GB0500785D0 (en) | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| CN1947717B (zh) * | 2005-10-14 | 2012-09-26 | 卓敏 | 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用 |
| US20070183995A1 (en) * | 2006-02-09 | 2007-08-09 | Conopco, Inc., D/B/A Unilever | Compounds useful as agonists of A2A adenosine receptors, cosmetic compositions with A2A agonists and a method for using the same |
| US8178509B2 (en) | 2006-02-10 | 2012-05-15 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
| GB0607950D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607953D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| PE20080361A1 (es) | 2006-04-21 | 2008-06-03 | Novartis Ag | Compuestos derivados de purina como activadores del receptor de adenosina a2a |
| US8188063B2 (en) | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
| JP2009541438A (ja) * | 2006-06-27 | 2009-11-26 | ビオヴィトルム・アクチボラゲット（プブリクト） | 治療用化合物 |
| EP2081932A2 (en) | 2006-06-27 | 2009-07-29 | BIOVITRUM AB (publ) | 2-o'-methyladenosine derivatives and their use as agonists or antagonists of an adenosine receptor |
| CA2657973A1 (en) | 2006-06-27 | 2008-01-03 | Biovitrum Ab (Publ) | Therapeutic compounds |
| EP1889846A1 (en) | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
| EP1903044A1 (en) | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
| WO2009061516A1 (en) * | 2007-11-08 | 2009-05-14 | New York University School Of Medicine | Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening |
| US8058259B2 (en) | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
| US20090181920A1 (en) * | 2008-01-09 | 2009-07-16 | Pgxhealth, Llc | Intrathecal treatment of neuropathic pain with a2ar agonists |
| US20100160351A1 (en) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| WO2010071865A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| CA2766937A1 (en) * | 2009-07-09 | 2011-01-13 | Cbt Development Limited | Combined preparation for use as a medicament |
| WO2011032175A1 (en) | 2009-09-14 | 2011-03-17 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
| CA2783859A1 (en) * | 2009-12-10 | 2011-06-16 | Institute Of Materia Medica, Chinese Academy Of Medical Sciences | N6-substituted adenosine derivatives and n6-substituted adenine derivatives and uses thereof |
| US20130109645A1 (en) * | 2010-03-31 | 2013-05-02 | The united States of America,as represented by Secretary,Dept.,of Health and Human Services | Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders |
| KR20140059246A (ko) * | 2011-09-22 | 2014-05-15 | 화이자 인코포레이티드 | 피롤로피리미딘 및 퓨린 유도체 |
| FR2981650B1 (fr) * | 2011-10-24 | 2013-12-27 | Univ Paris Curie | Analogues de nucleosides pour le traitement d'une infection virale et methode d'evaluation de la sensibilite audit traitement |
| US20160038526A1 (en) * | 2012-08-16 | 2016-02-11 | Thomas Jefferson University | Treatment of prostate cancer |
| US20150209379A1 (en) * | 2012-08-16 | 2015-07-30 | Thomas Jefferson University | Treatment of prostate cancer and hematologic neoplasms |
| EP2711008A1 (en) | 2012-09-19 | 2014-03-26 | Institut Univ. de Ciència i Tecnologia, S.A. | N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer |
| US9771390B2 (en) * | 2013-12-10 | 2017-09-26 | Scinopharm Taiwan, Ltd. | Process for the preparation of regadenoson |
| WO2018140734A1 (en) | 2017-01-27 | 2018-08-02 | Academia Sinica | Compound with analgesic effect for use in prevention and treatment of pain |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4861498A (enExample) * | 1971-12-01 | 1973-08-28 | ||
| BE792155A (fr) * | 1971-12-01 | 1973-05-30 | Takeda Chemical Industries Ltd | Nouveaux derives de l'adenosine et leur procede de production |
| DE2359536C2 (de) * | 1972-12-08 | 1984-08-02 | Takeda Chemical Industries, Ltd., Osaka | 2,6-Diaminonebularinderivate |
| JPS5549594B2 (enExample) * | 1972-12-08 | 1980-12-12 | ||
| JPS5461195A (en) * | 1977-10-21 | 1979-05-17 | Takeda Chem Ind Ltd | N2-substituted phenyl-2,6-diaminonebularin |
| JPS5461194A (en) * | 1977-10-21 | 1979-05-17 | Takeda Chem Ind Ltd | Preparation of n22substituted 2*66diaminonebularin |
| US4705758A (en) * | 1984-06-19 | 1987-11-10 | Warner-Lambert Company | Adenosine receptor assay and kit |
| US5013829A (en) * | 1989-04-26 | 1991-05-07 | University Of Iowa Research Foundation | Stable congener of 2',3'-dideoxyadenosine |
| US5679650A (en) * | 1993-11-24 | 1997-10-21 | Fukunaga; Atsuo F. | Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine |
| US5677290A (en) * | 1990-05-10 | 1997-10-14 | Fukunaga; Atsuo F. | Therapeutic use of adenosine compounds as surgical anesthetics |
| US5877180A (en) * | 1994-07-11 | 1999-03-02 | University Of Virginia Patent Foundation | Method for treating inflammatory diseases with A2a adenosine receptor agonists |
| US6174873B1 (en) * | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
| GB0228723D0 (en) * | 2002-12-09 | 2003-01-15 | Cambridge Biotechnology Ltd | Treatment of pain |
| GB0305150D0 (en) * | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Use of therapeutic compounds |
| GB0305149D0 (en) * | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Compounds for the treatment of pain |
| GB0305153D0 (en) * | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Identification of therapeutic compounds |
| GB0328323D0 (en) * | 2003-12-05 | 2004-01-07 | Cambridge Biotechnology Ltd | Synthesis of 2-substituted adenosines |
| US20090131651A1 (en) * | 2003-12-05 | 2009-05-21 | Giles Albert Brown | Synthesis of 2-substituted adenosines |
| GB0401292D0 (en) * | 2004-01-21 | 2004-02-25 | Cambridge Biotechnology Ltd | Synthesis of spongosine |
-
2005
- 2005-03-04 WO PCT/GB2005/000800 patent/WO2005084653A2/en not_active Ceased
- 2005-03-04 US US10/598,520 patent/US20080221060A1/en not_active Abandoned
- 2005-03-04 EA EA200800538A patent/EA014425B1/ru not_active IP Right Cessation
- 2005-03-04 AU AU2005218997A patent/AU2005218997B2/en not_active Expired - Fee Related
- 2005-03-04 SG SG200804350-7A patent/SG144146A1/en unknown
- 2005-03-04 MX MXPA06010075A patent/MXPA06010075A/es unknown
- 2005-03-04 CA CA002557285A patent/CA2557285A1/en not_active Abandoned
- 2005-03-04 EP EP05717878A patent/EP1749016A2/en not_active Withdrawn
- 2005-03-04 JP JP2007501345A patent/JP2007526291A/ja active Pending
- 2005-03-04 BR BRPI0508488-1A patent/BRPI0508488A/pt not_active IP Right Cessation
- 2005-03-04 KR KR1020067020304A patent/KR20070004792A/ko not_active Ceased
- 2005-03-04 EA EA200601642A patent/EA011099B1/ru not_active IP Right Cessation
-
2006
- 2006-09-26 NO NO20064365A patent/NO20064365L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007526291A5 (enExample) | ||
| AU2005218997B2 (en) | Adenosine receptor agonists | |
| US20090082471A1 (en) | Deuterium-enriched fingolimod | |
| US20090076161A1 (en) | Deuterium-enriched bupropion | |
| JPH0393784A (ja) | Ｎ―置換―４―ピリミジンアミンおよび―ピリミジンジアミン | |
| JP2006519824A5 (enExample) | ||
| JP2009541438A5 (enExample) | ||
| JP7618642B2 (ja) | インターロイキンの調節におけるプロドラッグ | |
| RU2009102531A (ru) | Терапевтические соединения | |
| RU2009102512A (ru) | Терапевтические соединения | |
| DE69115744T2 (de) | Konjugate von Difluoroglutaminsäure mit Fölaten und Antifölaten für die Behandlung von neoplastischen Krankheiten | |
| JP7744022B2 (ja) | 三環式ヤヌスキナーゼ（ｊａｋ）阻害剤および自己免疫疾患の治療におけるそれらの使用 | |
| JP2009541436A5 (enExample) | ||
| CN1946732A (zh) | 腺苷受体激动剂 | |
| US20090076097A1 (en) | Deuterium-enriched atazanavir | |
| CN120757533A (zh) | 杂芳基化合物、固体形式、制备方法及其用途 | |
| JP2930214B2 (ja) | チエニル酢酸誘導体、その製造方法、その使用方法並びにこれを含有する薬剤及びその製造方法 | |
| US20090076031A1 (en) | Deuterium-enriched bortezomib | |
| Somphon et al. | Characterization of donepezil prepared by cogrinding with salicylic acid and p-aminobenzoic acid | |
| WO2025256633A1 (en) | Method of treating moderate to severe active rheumatoid arthritis | |
| US20090082442A1 (en) | Deuterium-enriched lubiprostone | |
| JP2004502780A (ja) | アデノシン化合物及びそれを含む医薬組成物 | |
| US20090075991A1 (en) | Deuterium-enriched efavirenz | |
| US20090082468A1 (en) | Deuterium-enriched levalbuterol | |
| US20090076264A1 (en) | Deuterium-enriched rivaroxaban |